Assenagon Asset Management S.A. cut its stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 32.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 99,731 shares of the biopharmaceutical company's stock after selling 47,962 shares during the quarter. Assenagon Asset Management S.A. owned 0.15% of Xenon Pharmaceuticals worth $4,594,000 as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors and hedge funds have also recently modified their holdings of XENE. JPMorgan Chase & Co. raised its stake in shares of Xenon Pharmaceuticals by 33.4% in the first quarter. JPMorgan Chase & Co. now owns 6,371 shares of the biopharmaceutical company's stock worth $194,000 after purchasing an additional 1,596 shares during the last quarter. Citigroup Inc. grew its holdings in shares of Xenon Pharmaceuticals by 4,353.5% in the first quarter. Citigroup Inc. now owns 102,475 shares of the biopharmaceutical company's stock valued at $3,133,000 after acquiring an additional 100,174 shares in the last quarter. BlackRock Inc. grew its holdings in shares of Xenon Pharmaceuticals by 8.3% in the first quarter. BlackRock Inc. now owns 614,957 shares of the biopharmaceutical company's stock valued at $18,801,000 after acquiring an additional 47,385 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in shares of Xenon Pharmaceuticals by 0.6% in the first quarter. Dimensional Fund Advisors LP now owns 293,729 shares of the biopharmaceutical company's stock valued at $8,979,000 after acquiring an additional 1,783 shares in the last quarter. Finally, Allianz Asset Management GmbH grew its holdings in shares of Xenon Pharmaceuticals by 46.2% in the first quarter. Allianz Asset Management GmbH now owns 102,185 shares of the biopharmaceutical company's stock valued at $3,123,000 after acquiring an additional 32,280 shares in the last quarter. 95.45% of the stock is owned by hedge funds and other institutional investors.
Insider Buying and Selling
In related news, EVP Sherrington Robin sold 7,137 shares of the stock in a transaction on Thursday, March 7th. The stock was sold at an average price of $46.28, for a total value of $330,300.36. Following the sale, the executive vice president now owns 8,398 shares in the company, valued at $388,659.44. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other Xenon Pharmaceuticals news, Director Steven Gannon sold 13,000 shares of the firm's stock in a transaction dated Thursday, March 7th. The stock was sold at an average price of $46.28, for a total transaction of $601,640.00. Following the sale, the director now owns 2,000 shares in the company, valued at $92,560. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Sherrington Robin sold 7,137 shares of the firm's stock in a transaction dated Thursday, March 7th. The shares were sold at an average price of $46.28, for a total value of $330,300.36. Following the sale, the executive vice president now owns 8,398 shares in the company, valued at approximately $388,659.44. The disclosure for this sale can be found here. 5.43% of the stock is currently owned by company insiders.
Xenon Pharmaceuticals Price Performance
Shares of Xenon Pharmaceuticals stock traded down $0.91 during trading hours on Monday, reaching $42.14. The company had a trading volume of 240,125 shares, compared to its average volume of 422,104. Xenon Pharmaceuticals Inc. has a one year low of $27.99 and a one year high of $50.99. The business has a fifty day simple moving average of $46.10 and a 200 day simple moving average of $40.30. The firm has a market cap of $3.18 billion, a PE ratio of -15.49 and a beta of 1.15.
Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last posted its quarterly earnings results on Thursday, February 29th. The biopharmaceutical company reported ($0.64) EPS for the quarter, topping analysts' consensus estimates of ($0.76) by $0.12. During the same period in the prior year, the business earned ($0.57) earnings per share. Xenon Pharmaceuticals's revenue for the quarter was up .0% compared to the same quarter last year. On average, research analysts forecast that Xenon Pharmaceuticals Inc. will post -3.04 EPS for the current year.
Analyst Upgrades and Downgrades
Several equities analysts have recently issued reports on XENE shares. Stifel Nicolaus upped their target price on Xenon Pharmaceuticals from $53.00 to $62.00 and gave the company a "buy" rating in a report on Monday, December 18th. Robert W. Baird assumed coverage on Xenon Pharmaceuticals in a report on Friday, December 8th. They set an "outperform" rating and a $63.00 price objective for the company. JPMorgan Chase & Co. increased their price objective on Xenon Pharmaceuticals from $54.00 to $59.00 and gave the company an "outperform" rating in a report on Tuesday, December 19th. Needham & Company LLC increased their price objective on Xenon Pharmaceuticals from $50.00 to $62.00 and gave the company a "buy" rating in a report on Friday, March 1st. Finally, Bank of America increased their price objective on Xenon Pharmaceuticals from $52.00 to $56.00 and gave the company a "buy" rating in a report on Tuesday, January 2nd. One analyst has rated the stock with a sell rating and nine have issued a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $58.67.
Check Out Our Latest Analysis on XENE
Xenon Pharmaceuticals Profile
(
Free Report)
Xenon Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, a Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epileptic encephalopathy; and XEN1101, a Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders.
Further Reading
Before you consider Xenon Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xenon Pharmaceuticals wasn't on the list.
While Xenon Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report
